The prevalence of insomnia is higher among women and older individuals (Mellinger et al., 1985; Ford and Kamerow, 1989; Foley et al., 1995).
Insomnia and parasomnias following a stroke are treated using temporary hypnotic drug therapies, such as zolpidem or benzodiazepines.
Digoxin has been associated with both insomnia and daytime fatigue.
Among the general adult population affected by chronic pain, 50 percent complain of poor sleep and 44 percent complain of insomnia.
Forty percent of individuals diagnosed with insomnia also have a psychiatric disorder, according to a population-based study.
Stress is believed to play a leading role in activating the hypothalamic-pituitary axis, which sets the stage for chronic insomnia.
Researchers are investigating overlapping neural pathways for anxiety, arousal, and circadian disturbance as a potential pathophysiological link between insomnia and depression (Benca, 2005b).
Insomnia symptoms affect at least 10 percent of adults in the United States (Ford and Kamerow, 1989; Ohayon et al., 1997; Simon and VonKorff, 1997; Roth and Ancoli-Israel, 1999).
Behavioral approaches developed for insomnia may be useful for sleep loss, but no formal studies have been conducted specifically for sleep loss.
There have been no large-scale clinical trials examining the safety and efficacy of hypnotic agents for treating insomnia in children and adolescents.
Severe insomnia is often chronic, with approximately 85 percent of patients continuing to report the same symptoms and impairment months or years after their initial diagnosis.
Untreated residual insomnia is a risk factor for the recurrence of depression.
Nofzinger et al. (2005) hypothesize that the amygdala and other limbic structures of the brain are common pathways linking insomnia and depression.
Individuals with periodic limb movement disorder primarily complain of difficulty with sleep onset, sleep maintenance, insomnia, and/or hypersomnia.
Narcolepsy is associated with symptoms including excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, insomnia, autonomic behavior, and REM behavior disorder.
Dopaminergic agents used to treat Restless Legs Syndrome can have a stimulating effect that may exacerbate insomnia.
Insomnia patients frequently attribute their difficulty sleeping to having an overactive brain.
Evidence from preclinical and sleep neuroimaging studies suggests that multiple neural systems in the central nervous system are arranged hierarchically and contribute to arousal and insomnia complaints.
Kryger MH, Otake K, and Foerster J identified low body stores of iron as a correctable cause of insomnia in adolescents and teenagers in a 2002 study published in Sleep Medicine.
Vincent NK and Hameed H studied the relation between adherence and outcome in the group treatment of insomnia, as published in Behavioral Sleep Medicine in 2003.
Multiple neural systems arranged hierarchically in the central nervous system contribute to arousal and insomnia complaints, according to evidence from preclinical and sleep neuroimaging studies.
Harma, Tenkanen, Sjoblom, Alikoski, and Heinsalmi studied the combined effects of shift work and lifestyle on the prevalence of insomnia, sleep deprivation, and daytime sleepiness.
Insomnia is associated with depression, acting as both a risk factor and a manifestation of the condition.
Insomnia is the most commonly reported sleep problem according to Ohayon (2002).
Insomnia is used as a diagnostic symptom for major depression.
The choice of medication for a psychiatric disorder should be influenced by the nature of the patient's sleep complaint, such as using sedating antidepressants at night for insomnia or alerting antidepressants for excessive daytime sleepiness.
Insomnia is a common complication of stroke that may result from medication, inactivity, stress, depression, and brain damage.
Insomnia is a highly prevalent disorder that often goes unrecognized and untreated despite its adverse impact on health and quality of life (Benca, 2005a).
Continuous positive airway pressure (CPAP) is the treatment of choice for sleep-disordered breathing, while insomnia and parasomnias are treated using temporary hypnotic drug therapies such as zolpidem or benzodiazepines.
Insomnia is a symptom used in conjunction with other symptoms to diagnose major depression.
Beta-antagonists, which are used to treat hypertension, are commonly associated with fatigue, insomnia, nightmares, and vivid dreams.
In the study of 1,007 young adults by Breslau et al. (1996), the adjusted odds of developing depression after a history of insomnia were 3.95 (95% CI, 2.2–7.0).
Amiodarone, an antiarrhythmic agent, can cause nocturnal sleep disturbance, and digoxin has been associated with both insomnia and daytime fatigue.
Among individuals with chronic pain, 50 percent complain of poor sleep and 44 percent complain of insomnia.
Riemann and Voderholzer (2003) suggest that treating insomnia may prevent some cases of depression, though data supporting this are limited.
Fawcett et al. (1990) identified insomnia as a predictor of acute suicide among patients with mood disorders.
A study tracking more than 1,000 male physicians for 40 years found a longitudinal association between insomnia and depression.
Insomnia, excessive daytime sleepiness (hypersomnia), and parasomnia are the most frequent types of sleep disturbances associated with psychiatric disorders.
Risk factors for insomnia include a family history of insomnia (Dauvilliers et al., 2005), stressful lifestyles, medical and psychiatric disorders, and shift work (Edinger and Means, 2005).
Cognitive factors such as worry, rumination, and fear of sleeplessness perpetuate insomnia through behavioral conditioning.
Ohayon, Caulet, and Guilleminault (1997) investigated how the general population perceives their sleep and how those perceptions relate to complaints of insomnia.
There have been no formal studies conducted specifically on the use of behavioral approaches for sleep loss, although these approaches are used for insomnia.
Sleeping sickness is characterized by episodes of nocturnal insomnia and daytime sleep, but not hypersomnia.
Insomnia is associated with depression, acting as both a risk factor for and a manifestation of the condition (Ford and Kamerow, 1989; Livingston et al., 1993; Breslau et al., 1996; Weissman et al., 1997; Chang et al., 1997; Ohayon and Roth, 2003; Cole and Dendukuri, 2003).
Insomnia and major depression represent the most prevalent and best-studied comorbidity between sleep and psychiatric disorders.
Numerous medical conditions are associated with sleep disorders, including insomnia, hypersomnia, parasomnias, and sleep-related movement disorders.
The causes of sleep loss are multifactorial and categorized into two overlapping groups: lifestyle/occupational factors (such as shift work, prolonged working hours, jet lag, and irregular sleep schedules) and sleep disorders (such as insomnia, sleep-disordered breathing, restless legs syndrome, narcolepsy, and circadian rhythm disorders).
In a study sample, 16 percent of individuals with a history of insomnia at baseline developed depression, compared to 4.6 percent of individuals without a history of insomnia.
Corticosteroids, used to treat rheumatologic and immunologic disorders, cancer, and asthma, commonly cause side effects including sleep disturbances, insomnia, daytime hyperactivity, and mild hypomania (Wolkowitz et al., 1990).
Edinger JD and Means MK provided an overview of insomnia, covering definitions, epidemiology, differential diagnosis, and assessment in the 4th edition of 'Principles and Practice of Sleep Medicine'.
Studies have found that 15 to 20 percent of people diagnosed with insomnia also have major depression, according to Ford and Kamerow (1989) and Breslau et al. (1996).
Insomnia is a highly common symptom of major depression.
Longitudinal studies have established insomnia as a risk factor for major depression.
A large, population-based study by Ford and Kamerow (1989) found that insomnia was nearly twice as common in women than in men, though the researchers noted that reporting bias cannot be ruled out as a contributing factor.
Kripke DF, Garfinkel L, Wingard DL, Klauber MR, and Marler MR reported in 2002 that mortality is associated with sleep duration and insomnia.
Dopaminergic agents can have a stimulating effect that may exacerbate insomnia.
Insomnia in young men is associated with subsequent depression, according to the Johns Hopkins precursors study published in the American Journal of Epidemiology in 1997.
The two primary risk factors for insomnia are older age and female gender, as identified by Edinger and Means (2005).
Insomnia is treatable using a variety of behavioral and pharmacological therapies, which may be used alone or in combination.
Nofzinger et al. (2004b) provided functional neuroimaging evidence indicating that insomnia is associated with hyperarousal.
Hypolipidemic drugs, including atorvastatin and lovastatin, have been associated with reports of insomnia.
A 1993 longitudinal study by Hohagen et al. examined the prevalence and treatment of insomnia in general practice settings.
Dauvilliers Y, Morin C, Cervena K, Carlander B, Touchon J, Besset A, and Billiard M conducted family studies regarding insomnia.
Dauvilliers et al. (2005) conducted family studies on insomnia, published in the 'Journal of Psychosomatic Research'.
Insomnia is established as a risk factor for major depression based on longitudinal studies.
Insomnia is a predictor of acute suicide among patients with mood disorders, according to Fawcett et al. (1990).
Daytime consequences of insomnia include tiredness, lack of energy, difficulty concentrating, and irritability.
One hypothesis for the link between insomnia and depression is that chronic insomnia increases activity of the hypothalamic-pituitary-adrenal axis, which contributes to depression (Perlis et al., 2005).
Sedating antidepressants, antihistamines, and antipsychotics are used to treat insomnia, but their efficacy and safety for this purpose have not been thoroughly studied (Walsh et al., 2005).
The efficacy and safety of sedating antidepressants, antihistamines, and antipsychotics for treating insomnia have not been thoroughly studied (Walsh et al., 2005).
Insomnia is conceptualized as a state of hyperarousal.
Perlis et al. authored a chapter on the etiology and pathophysiology of insomnia in the 2005 book 'Principles and Practice of Sleep Medicine' (4th edition).
Forty percent of individuals diagnosed with insomnia also have a psychiatric disorder.
Insomnia is a highly prevalent disorder that often goes unrecognized and untreated despite its adverse impact on health and quality of life (Benca, 2005a).
The DSM-IV lists sleep disturbances as diagnostic criteria for certain psychiatric disorders, such as using insomnia as a symptom to diagnose major depression (APA, 1994).
Hypolipidemic drugs such as atorvastatin and lovastatin have been associated with reports of insomnia, although placebo-controlled clinical trials of lovastatin, simvastatin, and pravastatin did not appear to increase sleep disturbance.
Simon GE and VonKorff M studied the prevalence, burden, and treatment of insomnia in primary care settings.
Kripke et al. (2002) found an association between sleep duration, insomnia, and mortality rates in a study published in Archives in General Psychiatry.
Insomnia is a highly prevalent disorder that frequently remains unrecognized and untreated, despite having an adverse impact on an individual's health and quality of life.
Common sleep conditions include sleep loss, sleep-disordered breathing, insomnia, narcolepsy, restless legs syndrome, parasomnias, sleep-related psychiatric disorders, sleep-related neurological disorders, sleep-related medical disorders, and circadian rhythm sleep disorders.
Adults with insomnia have higher levels of cortisol and adrenocorticotropic hormone (ACTH) over a 24-hour period compared to normal sleepers, indicating activation of the hypothalamic-pituitary-adrenal axis.
Most sleep disorders are characterized by excessive daytime sleepiness, difficulty initiating or maintaining sleep, or abnormal movements, behaviors, and sensations occurring during sleep.
Insomnia is the most commonly reported sleep problem.
Ohayon (2002) reviewed the epidemiology of insomnia, identifying current knowledge and remaining research gaps.
Perpetuating factors for insomnia include light exposure and unstable sleep schedules, as noted by Partinen and Hublin in 2005.
Nowell et al. (1997) identified clinical factors that contribute to the differential diagnosis of primary insomnia versus insomnia related to mental disorders.
Sleep disturbances, including insomnia, excessive daytime sleepiness (hypersomnia), and parasomnia, are common features of psychiatric disorders and are listed as diagnostic criteria in the DSM-IV (APA, 1994).
Simon and VonKorff (1997) studied the prevalence, burden, and treatment of insomnia in primary care settings.
Treating insomnia may prevent some cases of depression, though limited data are available to support this possibility (Riemann and Voderholzer, 2003).
Katz and McHorney (1998) identified clinical correlates of insomnia in patients suffering from chronic illness.
The prevalence of insomnia is higher among women and older individuals.
The adjusted odds of developing depression for individuals with a history of insomnia were 3.95 (95% CI, 2.2–7.0).
Treating both insomnia and comorbid psychiatric conditions can improve patient functioning and potentially improve adherence to therapy.
A 1997 study by Hauri et al. examined the efficacy of combining behavioral therapy with hypnotics for the treatment of insomnia.
Researchers hypothesize that insomnia and depression may be linked by common pathophysiology involving overlapping neural pathways for anxiety, arousal, and/or circadian disturbance, as suggested by Benca (2005b).
Diagnosis of a circadian rhythm sleep disorder requires meeting three criteria: (1) a persistent or recurrent pattern of sleep disturbance due primarily to an alteration of the circadian timekeeping system or a misalignment between endogenous circadian rhythm and exogenous factors affecting sleep timing and duration; (2) the circadian-related disruption leads to insomnia, excessive sleepiness, or both; and (3) the sleep disturbance is associated with impairment of social, occupational, or other functions.
The adjusted odds of developing a psychiatric disorder following a history of insomnia were highest for depression, with an odds ratio of 3.95 (95% CI, 2.2–7.0).
In a population-based study, 40 percent of individuals diagnosed with insomnia also have a psychiatric disorder, according to Ford and Kamerow (1989).
Insomnia symptoms affect at least 10 percent of adults in the United States (Ford and Kamerow, 1989; Ohayon et al., 1997; Simon and VonKorff, 1997; Roth and Ancoli-Israel, 1999).
Nonbenzodiazepine hypnotics are advantageous for treating insomnia because they generally have shorter half-lives, resulting in fewer next-day impairments, though they may be less effective at maintaining sleep throughout the night compared to other options, according to Morin (2005) and Benca (2005a).
Lingjaerde O, Bratlid T, and Hansen T conducted an explorative, controlled trial on the treatment of insomnia during the 'dark period' in northern Norway using light treatment, published in Acta Psychiatrica Scandinavia in 1985.
A 2005 study by Dauvilliers Y, Morin C, Cervena K, Carlander B, Touchon J, Besset A, and Billiard M investigated family history in cases of insomnia.
Morin, Mimeault, and Gagne studied nonpharmacological treatments for insomnia in elderly populations, published in the Journal of Psychosomatic Research in 1999.
A study of 10,000 adults by Weissman and colleagues (1997) found that insomnia increased the risk of major depression fivefold and increased the risk of panic disorder 20-fold (OR = 20.3, 95% CI, 4.4–93.8).
The most efficacious pharmacological therapies for insomnia are hypnotic agents, specifically benzodiazepine or nonbenzodiazepine hypnotics, according to Nowell et al. (1997).
A greater prevalence of insomnia may contribute to the rise in sleep loss, though likely to a lesser extent than occupational or lifestyle changes.
44 percent of the adult population with chronic pain complain of insomnia.
The prevalence of insomnia is higher among women and older individuals (Mellinger et al., 1985; Ford and Kamerow, 1989; Foley et al., 1995).
Insomnia in the context of narcolepsy is typically characterized by difficulty maintaining sleep.
Weissman et al. (1997) studied the morbidity associated with insomnia that is uncomplicated by psychiatric disorders.
The 1991 National Sleep Foundation Survey examined the daytime consequences and correlates of insomnia in the United States, as reported by T. Roth and S. Ancoli-Israel in a 1999 Sleep journal supplement.
Harma et al. (1998) studied the combined effects of shift work and lifestyle on the prevalence of insomnia, sleep deprivation, and daytime sleepiness.
There have been no large-scale trials examining the safety and efficacy of hypnotic agents for treating insomnia in children and adolescents (Walsh et al., 2005).
A longitudinal study of 1,007 young adults at a health maintenance organization found that a history of insomnia at baseline predicted the new onset of depression and other psychiatric disorders, including anxiety, alcohol abuse, drug abuse, and nicotine dependence, over a 3.5-year period.
Medical conditions are associated with various sleep disorders, including insomnia, hypersomnia, parasomnias, and sleep-related movement disorders, which are categorized in the International Classification of Sleep Disorders.
Fava M identified daytime sleepiness and insomnia as correlates of depression.
A 1997 study published in the American Journal of Epidemiology titled 'Insomnia in young men and subsequent depression' found a link between insomnia in young men and the subsequent development of depression.
A longitudinal study tracking more than 1,000 male physicians for 40 years examined the relationship between insomnia and psychiatric disorders.
Individuals with insomnias associated with depression exhibit abnormal activity in neocortical structures responsible for controlling executive function and modulating behavior related to basic arousal and emotions, according to Nofzinger et al. (2004a, 2005).
Benzodiazepine and nonbenzodiazepine hypnotics are the most efficacious pharmacological therapies for insomnia (Nowell et al., 1997).
Beszterczey and Lipowski (1977) reported on the prevalence and nature of insomnia in cancer patients.
Insomnia symptoms affect at least 10 percent of adults in the United States.
Common sleep conditions identified by the Institute of Medicine (US) Committee on Sleep Medicine and Research include sleep loss, sleep-disordered breathing, insomnia, narcolepsy, restless legs syndrome, parasomnias, sleep-related psychiatric disorders, sleep-related neurological disorders, sleep-related medical disorders, and circadian rhythm sleep disorders.
Insomnia worsens clinical outcomes in patients with depression, schizophrenia, and alcohol dependence.
One hypothesis for the link between insomnia and depression is that common neural pathways involve the amygdala and other limbic structures of the brain (Nofzinger et al., 2005).
Harma M., Tenkanen L., Sjoblom T., Alikoski T., and Heinsalmi P. (1998) studied the combined effects of shift work and lifestyle on the prevalence of insomnia, sleep deprivation, and daytime sleepiness in the 'Scandinavian Journal of Work, Environment and Health'.
Insomnia is defined as having difficulty falling asleep, maintaining sleep, or experiencing short sleep duration despite having adequate opportunity for a full night's sleep.
There are approximately 90 distinct sleep disorders, most of which are characterized by symptoms such as excessive daytime sleepiness, difficulty initiating or maintaining sleep, or abnormal events occurring during sleep.
Insomnia has a measurable prevalence, burden, and treatment profile in primary care settings.
Most potential mechanisms explaining sleep changes in psychiatric disorders focus specifically on the relationship between insomnia and depression.
The 1991 National Sleep Foundation Survey identified daytime consequences and correlates of insomnia in the United States.